Adrian Vella, MD
Endocrinology, Diabetes & Metabolism · Rochester, MNNPI 1104890607
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Boehringer Ingelheim International GmbH accounts for 63.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $11,101 and has fallen 51.9% since, to $5,345 in 2025.
Across 16 payments — averaging $1630.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$16K
- Novo Nordisk$9K
- Zealand Pharma A/s$300
- Medtronic$109
Across 37 payments — averaging $44,923 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$1.4M
- Recordati_rare_diseases_inc.$214K
- Sanofi US Services Inc.$54K
- Xeris Pharmaceuticals, Inc.$5K
- Dexcom, Inc.$2K
What the payments were for
- Consulting fees$11,36144%
- Travel & lodging$14,46955%
- Food & beverage$2601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 10 | $16,446 |
| Novo Nordisk | 4 | $9,234 |
| Zealand Pharma A/s | 1 | $300 |
| Medtronic | 1 | $109 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dasiglucagon$300
- Minimed 670G System$109
How this compares
$26,090 in reported general payments places this provider in the 80th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $43,551 |
| MounjaroTirzepatide | 28 | $34,226 |
| Testosterone | 21 | $9,557 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $4,464 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $4,419 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,328 |
| Hydrocortisone | 28 | $3,136 |
| Cabergoline | 29 | $2,084 |
| Levothyroxine Sodium | 41 | $690 |
| Metformin Hcl | 20 | $255 |
| Lisinopril | 24 | $196 |
| Metformin Hcl ErMetformin Hcl | 14 | $181 |
| Atorvastatin Calcium | 22 | $139 |
| Amlodipine Besylate | 11 | $15 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $9,234 | $43,55128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Rochester
- Marjorie Ann MalbasRochester$222K
- Irina BancosRochester$114K
- Maria CastroRochester$63K
- Marius StanRochester$59K
- Matthew DrakeRochester$41K
- Manpreet MundiRochester$39K
- Yogish KudvaRochester$38K
- Bart ClarkeRochester$36K
- Robert RizzaRochester$30K
- Michael JensenRochester$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.